BioSpace News Archive

The National Disease Research Interchange, in collaboration with the University of Maryland School of Medicine and Johns Hopkins All Children’s Hospital, has been awarded a research grant of $14.4M by the National Institutes of Health with a goal to transform our knowledge of how much genetic variation there is in cells and tissues throughout our bodies.

Inimmune announced that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will be a Keynote speaker at the University of Washington, Institute for Translational Health Sciences Expo ’23.

Zymo Research, a leading provider of microbiology research tools, has officially launched its Full-Length 16S Sequencing Service, offering researchers high-quality, full-length 16S rRNA gene sequencing for microbiome analysis.

Aitia, the leader in the development and application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced a collaboration with Servier to create new Gemini Digital Twins to help in the fight against Pancreatic Cancer.

POXEL SA (Euronext: POXEL - FR0012432516) today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2023.

Aurinia Pharmaceuticals Inc. announced voting results for its annual general meeting of shareholders held on May 17, 2023.

The annual general meeting was held in AlzeCure Pharma AB.

A new study adds to an emerging, radically new picture of how bacterial cells continually repair faulty sections of their DNA.

Bausch Health Companies Inc. (NYSE/TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. District Court of Delaware in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc., has denied Norwich Pharmaceuticals’ motion to modify the Court’s final judgment that prevents the U.S. Food and Drug Administration (FDA) from approving Norwich’s abbreviated new drug application (ANDA) for XIFAXAN® (rifaximin) 550 mg before Oct. 2, 2029.

AB Science SA (Euronext – FR0010557264 – AB) today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, during an Panel Discussion at the ALS Drug Development Summit in Boston, USA (May 16-18, 2023).